Translate
Agenus Inc.
About
Agenus Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 4 2026
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
Apr 21 2026
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Apr 17 2026
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
Apr 3 2026
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
Apr 1 2026
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Recent Videos
Agenus Stakeholder Webcast | March 31, 2026
Apr 14, 2026
AGEN STOCK : POTENTIAL BREAKOUT | AGENUS STOCK
Apr 07, 2026
Agenus (AGEN|$101.3M) - 2025 Full Year Earnings Analysis
Mar 16, 2026
EPISODE 3: Garo Armen, CEO of Agenus and chairman of the Children of Armenia Fund
Mar 11, 2026